The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

D. Arber; A. Orazi; R. Hasserjian; J. Thiele; M. Borowitz; M. L. Le Beau; C. Bloomfield; M. Cazzola; J. Vardiman

DOI:10.1182/blood-2016-03-643544

Corpus ID: 18338178

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

@article{Arber2016The2R,
  title={The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.},
  author={D. Arber and A. Orazi and R. Hasserjian and J. Thiele and M. Borowitz and M. L. Le Beau and C. Bloomfield and M. Cazzola and J. Vardiman},
  journal={Blood},
  year={2016},
  volume={127 20},
  pages={
          2391-405
        }
}

D. Arber, A. Orazi, +6 authors J. Vardiman

Published 2016

Medicine

Blood

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. [...] Key Method The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical…Expand Abstract

View PDF

Share This Paper

3,517 Citations

Highly Influencial Citations

321

Background Citations

1,197

Methods Citations

516

Results Citations

Supplemental Presentations

PRESENTATION SLIDES

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Explore Further

Discover more papers related to the topics discussed in this paper

Tables and Topics from this paper.

Tables

Paper Mentions

INTERVENTIONAL CLINICAL TRIAL

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGFβ signaling is known to be abnormally… Expand

Conditions	Myeloproliferative Neoplasm
Intervention	Drug

Weill Medical College of Cornell University

September 2019 - September 2023

OBSERVATIONAL CLINICAL TRIAL

Immunophenotyping and Xist Gene in AML

Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood.Several studies have… Expand

Conditions	Acute Myeloid Leukemia
Intervention	Diagnostic Test, Genetic

Assiut University

May 2020 - December 2022

INTERVENTIONAL CLINICAL TRIAL

High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

Myelodysplastic syndromes (MDS) are the most frequent myeloid neoplasms in Western Countries.They mainly affect patients aged 65 years or older. This is a very heterogenous group… Expand

Conditions	High-risk Myelodysplastic Syndromes With Excess Blasts
Intervention	Diagnostic Test

Central Hospital, Nancy, France

October 2017 - January 2022

OBSERVATIONAL CLINICAL TRIAL

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

The RUXOREL-MF observational study includes patients with primary and post-essential thrombocythemia/post-polycythemia vera myelofibrosis (MF) being treated with the oral JAK1… Expand